Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

HALOPERIDOL vs OTHER ANTIPSYCHOTICS

Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for long‐term aggression in psychosis 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE vs CLOZAPINE ‐ all data short term

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse

It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 2.71 [0.3, 24.08]
2 studies · 50 participants
Very low

PERPHENAZINE vs antipsychotics

Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia

It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Perphenazine for schizophrenia 2015 · Cochrane Headline outcomes only
RR 1.36 [0.23, 8.16]
4 studies · 416 participants
Very low